drugset
drugset / Trial / NCT05888207

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

NCT05888207 ↗

Phase 1 Completed 16 enrolled AstraZeneca Parexel · collab
NaSequentialOpen-labelOther

Summary

This study will assess the effects of strong CYP1A2 (Cytochrome P450 1A2) inhibitor (fluvoxamine) on savolitinib exposure in healthy male subjects, performed at a single clinical unit.

Timeline

Start
2023-06-02
Primary completion
2023-08-17
Completion
2023-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown — Oral
Subject Savolitinib Small molecule — Oral

Indications

No indication recorded.